Skip to main content

Advertisement

Table 6 The GSA result by a network-expanded and cross-species GSA (case example 3)

From: gsGator: an integrated web platform for cross-species gene set analysis

Rank Set size Overlap P-value Q-value Mouse phenotype
1 79 10 9.9.E-21 7.5.E-17 Abnormal blood coagulation
2 73 5 1.9.E-09 7.0.E-06 Increased bleeding time
3 37 4 1.3.E-08 3.4.E-05 Gastrointestinal hemorrhage
4 150 5 7.0.E-08 1.2.E-04 Increased leukocyte cell number
5 57 4 7.9.E-08 1.2.E-04 Abnormal cell adhesion
6 1258 9 1.5.E-07 1.9.E-04 Premature death
7 75 4 2.4.E-07 2.6.E-04 Decreased susceptibility to endotoxin shock
8 80 4 3.1.E-07 2.9.E-04 Thrombosis
9 94 4 6.0.E-07 5.0.E-04 Increased monocyte cell number
10 30 3 1.3.E-06 9.1.E-04 Abnormal cellular extravasation
11 277 5 1.4.E-06 9.1.E-04 Hemorrhage
12 3 2 1.5.E-06 9.1.E-04 Purpura
13 33 3 1.7.E-06 1.0.E-03 Decreased susceptibility to bacterial infection induced morbidity/mortality
14 153 4 4.1.E-06 2.1.E-03 Decreased erythrocyte cell number
15 153 4 4.1.E-06 2.1.E-03 Increased neutrophil cell number
16 50 3 6.1.E-06 2.9.E-03 Impaired macrophage chemotaxis
17 51 3 6.5.E-06 2.9.E-03 Decreased platelet aggregation
18 6 2 7.2.E-06 3.0.E-03 Abnormal circulating fibrinogen level
19 7 2 1.0.E-05 3.8.E-03 Uterine hemorrhage
20 7 2 1.0.E-05 3.8.E-03 Petechiae
21 60 3 1.1.E-05 3.8.E-03 Impaired neutrophil recruitment
22 8 2 1.4.E-05 4.4.E-03 Increased susceptibilityto infection induced morbidity/mortality
23 65 3 1.4.E-05 4.4.E-03 Abnormal leukocyte migration
24 211 4 1.5.E-05 4.6.E-03 Increased sensitivityto induced morbidity/mortality
25 69 3 1.6.E-05 4.8.E-03 Increased eosinophil cell number
26 70 3 1.7.E-05 4.8.E-03 Abnormal myelopoiesis
27 9 2 1.7.E-05 4.8.E-03 Hemothorax
28 72 3 1.8.E-05 4.9.E-03 Abnormal cell migration
29 81 3 2.6.E-05 6.4.E-03 Internal hemorrhage
30 11 2 2.6.E-05 6.4.E-03 Skin hemorrhage
31 11 2 2.6.E-05 6.4.E-03 Abnormal platelet aggregation
32 86 3 3.1.E-05 7.3.E-03 Decreased angiogenesis
33 13 2 3.8.E-05 8.5.E-03 Decreased susceptibility to induced choroidal neovascularization
34 100 3 4.9.E-05 1.1.E-02 Abnormal inflammatory response
35 289 4 4.9.E-05 1.1.E-02 Anemia
36 15 2 5.0.E-05 1.1.E-02 Pulmonary alveolar hemorrhage
37 18 2 7.3.E-05 1.5.E-02 Abnormal uterine environment
38 20 2 9.1.E-05 1.8.E-02 Abnormal physiological neovascularization
39 21 2 1.0.E-04 1.9.E-02 Hemoperitoneum
40 22 2 1.1.E-04 2.0.E-02 Pregnancy-related premature death
41 22 2 1.1.E-04 2.0.E-02 Abnormal platelet activation
42 133 3 1.1.E-04 2.0.E-02 Decreased platelet cell number
43 24 2 1.3.E-04 2.3.E-02 Increased susceptibility to fungal infection
44 33 2 2.5.E-04 4.3.E-02 Decreased cerebral infarction size
45 180 3 2.7.E-04 4.6.E-02 Pallor
  1. The related annotations to venous thrombosis is indicated in bold type.